M E D Chamuleau
Overview
Explore the profile of M E D Chamuleau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Jonge A, Bult J, Karssing D, Nijland M, Chamuleau M, Brink M
Blood Cancer J
. 2024 Jan;
14(1):2.
PMID: 38177113
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III-IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited stage (LS) I-II is unclear. Therefore,...
2.
Al-Sarayfi D, Brink M, Chamuleau M, Brouwer R, van Rijn R, Issa D, et al.
Am J Hematol
. 2023 Nov;
99(2):216-222.
PMID: 38014799
For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from...
3.
Eertink J, Zwezerijnen G, Heymans M, Pieplenbosch S, Wiegers S, Duhrsen U, et al.
Blood
. 2023 Mar;
141(25):3055-3064.
PMID: 37001036
The objective of this study is to externally validate the clinical positron emission tomography (PET) model developed in the HOVON-84 trial and to compare the model performance of our clinical...
4.
Eertink J, Arens A, Huijbregts J, Celik F, de Keizer B, Stroobants S, et al.
Eur J Nucl Med Mol Imaging
. 2021 Sep;
49(3):943-952.
PMID: 34476551
Purpose: MYC gene rearrangements in diffuse large B-cell lymphoma (DLBCL) patients are associated with poor prognosis. Our aim was to compare patterns of 2[F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (PET/CT)...
5.
Issa D, Seefat R, Visser O, Zweegman S, Lugtenburg P, Dinmohamed A, et al.
Blood
. 2021 Jan;
137(20):2848-2851.
PMID: 33512487
No abstract available.
6.
Oosten L, Chamuleau M, Thielen F, de Wreede L, Siemes C, Doorduijn J, et al.
Ann Hematol
. 2017 Dec;
97(2):255-266.
PMID: 29209924
Burkitt lymphoma is an aggressive B cell malignancy accounting for 1-2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is effective but associated with considerable toxicity. In this observational...
7.
Sieswerda E, Schade R, Bosch T, de Vries J, Chamuleau M, Haarman E, et al.
Clin Microbiol Infect
. 2017 May;
23(10):779-781.
PMID: 28487169
No abstract available.
8.
de Jonge A, Roosma T, Houtenbos I, Vasmel W, van de Hem K, de Boer J, et al.
Eur J Cancer
. 2016 Jan;
55:140-6.
PMID: 26820684
In the past decade, patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) were treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. Standard treatment is now changing as...
9.
Jansen Of Lorkeers S, Hart E, Tang X, Chamuleau M, Doevendans P, Bolli R, et al.
J Cardiovasc Transl Res
. 2014 May;
7(5):475-82.
PMID: 24831573
Stem cell therapy is a promising strategy in promoting cardiac repair in the setting of ischemic heart disease. Clinical and preclinical studies have shown that cell therapy improves cardiac function....
10.
Vos J, Minnema M, Wijermans P, Croockewit S, Chamuleau M, Pals S, et al.
Neth J Med
. 2013 Mar;
71(2):54-62.
PMID: 23462052
On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of...